# A Study to Investigate the Effects on Blood Pressure and Pulse Rate of a Single 100mg Dose of Sildenafil in Patients With Benign Prostatic Hyperplasia Who Are Being Treated With Doxazosin

> **NCT00645034** · PHASE2 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 20 (actual)

## Conditions studied

- Benign Prostatic Hyperplasia

## Interventions

- **DRUG:** placebo
- **DRUG:** sildenafil

## Key facts

- **NCT ID:** NCT00645034
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-11
- **Primary completion:** —
- **Final completion:** 2003-07
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2021-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00645034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00645034, "A Study to Investigate the Effects on Blood Pressure and Pulse Rate of a Single 100mg Dose of Sildenafil in Patients With Benign Prostatic Hyperplasia Who Are Being Treated With Doxazosin". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00645034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*